Cholinergic neurons—keeping check on amyloid β in the cerebral cortex
- 1Department of Translational Brain Research, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
- 2Center for Neuropathology and Prion Research, Ludwig Maximilian University, Munich, Germany
- 3Munich Cluster for Systems Neurology (SyNerg), Munich, Germany
- 4Faculty of Science and Health, School of Biotechnology, Dublin City University, Dublin, Ireland
The physiological relevance of p75 neurotrophin receptor-mediated internalization of ligands with no apparent trophic functions by nerve cells remains unclear. Herein, we propose a homeostatic role for this in clearance of amyloid β (Aβ) in the brain. We hypothesize that uptake of Aβ in conjunction with p75NTR followed by its degradation in lysosomes endows cholinergic basalo-cortical projections enriched in this receptor a capacity for maintaining physiological levels of this peptide in target areas. Thus, in addition to the diffuse modulator influence and channeling of extra-thalamic signals, cholinergic innervations could supply the cerebral cortex with an elaborate system for Aβ drainage. Interpreting the emerging relationship of molecular data with recognized role of cholinergic modulator system in regulating cortical activity should provide new insights into the brain physiology and mechanisms of neuro-degenerative diseases.
Depositions of Aβ plaques and neuro-fibrillary tangles in limbic, para-limbic, and associative cortices with depletion of acetylcholine (ACh) have been recognized as reliable pathological hallmarks of Alzheimer's disease (AD) (Davies and Maloney, 1976; Mesulam, 2004). Discovery of the functional relationship between the cognitive decline and loss of cholinergic markers in the plaque laden cerebral cortex with degeneration of source neurons in the nucleus basalis Meynert (NBM) of basal forebrain (BF) marked a major breakthrough in interpreting the AD since its first account in 1907 by Alzheimer (1907). Indeed, closure was reached in the 1970s of the descriptive “anamneses morbid” and a transmitter-based hypothesis of AD was launched, with hopeful therapeutic projections. Alas, both the functional vision and optimistic curative forecasts were doomed to defeat, with in-depth research revealing an incredibly composite nature of the pathology, gradually shifting the heuristic spotlight back onto descriptive grounds and focusing the main emphasis on plaque and tangle related processes (Selkoe, 1997; Holtzman et al., 2011). Thus, the significance of cholinergic deficiency in the patho-physiology of the disease was relegated to the secondary rank of undecided importance. Without doubt, such dialectical back-tracking owes itself to tough questions being identified yet not addressed explicitly by the cholinergic hypothesis (Francis et al., 1999; Terry and Buccafusco, 2003). Indeed, neither the cellular-molecular basis for the greater vulnerability of cholinergic axons nor the partial restorations of mnemonic and cognitive functions by anti-cholinesterase drugs have been mechanistically explained. Conceivably, most challenging to the cholinergic theory of AD were reports doubting the selective loss of cholinergic axons as well as the causal relationship between the degeneration of neurons supplying ACh to the cerebral mantle with plaque- or tangle-associated pathology (Davis et al., 1999; Zarow et al., 2003). Along with overtly intact brainstem and striatal cholinergic neurons in the AD brain with absence of amyloid plaque and neurofibrillary tangle related pathology in subjects affected by atrophy of hind-brain cholinergic nuclei, these unsettled views suggested important unknowns in the biology of the forebrain cholinergic system, in all likelihood, extending its functions beyond the mere supply of ACh to the cerebral cortex.
What is unique about BF cholinergic neurons and why controversy persists over their significance in the patho-biology of AD for over almost a half of a century? In addition to being one of the largest neurons in the forebrain, which channel the rostral stream of signals from the reticular core and deep brain nuclei to the cerebral mantle (extra-thalamic route), these represent the only population of nerve cells in the adult forebrain that expresses unusually high level of the p75 neurotrophin receptor (p75NTR) (Hartig et al., 1998; Mufson et al., 2008). Like other members of the tumor necrosis factor (TNF) receptor family to which it belongs, p75NTR lacks endogenous catalytic activity and relies on the recruitment of co-receptors and signaling molecular partners for initiating the cellular response. Distinctly, however, p75NTR is the only member of this family that binds neurotrophins and brain-derived growth factors, playing a key role in activation of survival or apoptotic processes (Costantini et al., 2005; Coulson et al., 2009; Knowles et al., 2009) (Figure 1). To make matters more complex, p75NTR also binds with high affinity to a range of collateral ligands of no obvious neurotrophic function, including tetanus toxins, some viral glycoproteins, prion protein and Aβ peptide (Yaar et al., 1997; Dechant and Barde, 2002). Although the fate of ligands bound and internalized in complex with p75NTR is a matter of ongoing research, emerging evidence suggests at least three routes that can be pursued by the endocytosed Aβ (Bronfman and Fainzilber, 2004; Trajkovic et al., 2008; Sorkin and von Zastrow, 2009): (1) advancement via early endosomes and trans-Golgi networks into recycling compartments with partial back-fusion to surface membranes; (2) formation of signaling endosomes to influence nuclear function and gene expression and (3) maturation into late endosomes destined to fusion with lysosomes and degradation of cargo or escape through sorting in MVBs and release in association with exosomes (Figure 1). Due to such special arrangements, the unusually high expression of p75NTR in BF cholinergic neurons is likely to render the later particularly responsive to a range of putative ligands, including Aβ (Counts and Mufson, 2005; Coulson et al., 2009; Knowles et al., 2009). On the other hand, the capacity to sequestrate and degrade Aβ by cholinergic neurons and their projections is expected to play a pivotal role in the maintenance of low physiological levels of Aβ in axon terminal fields. This intuitive notion received experimental backing from recent studies in primary neuronal cultures of BF, which demonstrated robust internalization and transport of fluor labeled Aβ in conjunction with a p75NTR antibody (IgG192-Cy3) in cholinergic neurons, with its accumulation in lysosomes (Ovsepian and Herms, 2013; Ovsepian et al., 2013). Unlike regulated endocytosis which is reliant on high voltage gated Ca2+ influx and canonical neuronal SNAREs (e.g., SNAP-25, syntaxin 1/2 and VAMP 1/2), the internalization of p75NTR requires Ca2+ entry via low-threshold T-type channels or mobilization of Ca2+ from thapsigargin-sensitive internal stores and is independent of VAMP 1/2 and SNAP-25. Quantitative analysis of the distribution of IgG192-Cy3 revealed its deposition in acidifying late endosomes and lysosomes—key organelles involved in degradation of cellular debris and metabolites. Although limited data is available on the relevance of these processes to Aβ clearance within the intact brain, injection of IgG192-Cy3 into the medial frontal cortex or lateral cerebral ventricle in rats also revealed its rapid axonal internalization followed by retrograde transport and accumulation in putative lysosomes of cholinergic neurons in the BF (Hartig et al., 1998; Ovsepian et al., 2013).
Figure 1. (A) Schematic illustration of the human BF cholinergic projections with modulator and neurotrophic mechanisms: coronal brain section. Long-range cholinergic axons and collaterals supply the entire cerebral mantle with acetylcholine (upper), which via muscarinic (mAChR1–5) and nicotinic (nAChRI-III) cholinergic receptors regulate a wide range of cortical processes and functions (lower). The diffuse projections through retrograde axonal transport channel back to the basal forebrain cholinergic neurons signaling endosomes and organelles, which carry trophic factors and other ligands bound to trkA-C and p75NTR. The homeostatic significance of p75NTR-mediated uptake of Aβ and its degradation in lysosomes of basal forebrain cholinergic neurons is discussed. (B) Graphical illustration of 3 possible intra-cellular routes taken by p75NTR (and Aβ) carrying endosomes. After internalization via clathrin-dependent and -independent processes, a fraction of p75NTR (and Aβ) loaded endosomes is recycled back to the plasma membrane, whereas the rest is sorted to signaling endosomes and multivesicular bodies (MVBs). From here, bulk of the cargo is degraded in hybrid MVB—lysosomal compartments, which comprise the primary metabolic hot spots of Aβ proteolysis (Mullins and Bonifacino, 2001) while a minute fraction escapes from degradation through MVB sorting into exosomes and becomes available for exocytotic released from the cell (Rajendran et al., 2006; Trajkovic et al., 2008). Abbreviations: EE and RE—early and recycling endosomes, respectively; ER—endoplasmic reticulum; SE—signaling endosomes (SE); Nuc.—nucleus; LE and LS—late endosomes and lysosomes, respectively.
Thus, it emerges that in addition to modulator functions reliant on synaptic release of ACh (Figure 1) and muscarinic (M1 and M3) receptor-mediated regulation of the processing of amyloid precursor protein (APP) (Nitsch et al., 1993; Fisher, 2012), diffuse cholinergic innervations of the cerebral cortex may also contribute to Aβ clearance. While further research is warranted to establish the contribution of the latter process to the multifarious mechanisms of regulation of Aβ homeostasis, direct evidence for dissociation of cognitive and anti-amyloidogenic functions of the BF cholinergic system has been provided recently (Wang et al., 2011; Laursen et al., 2013). Indeed, unlike the selective lesion of cholinergic cells with p75NTR targeting neurotoxin (IgG192-saporin) in AD APPswe/PS1dE9 mice, exhibiting cognitive deficit and enhanced deposition of Aβ in several cortical regions, genetic deletion of p75NTR without ablation of cholinergic neurons led to enhanced cortical Aβ loading in the absence of cognitive deficit. Together with clinical data demonstrating that neither Aβ accumulation nor cognitive deficit in AD can be attributed exclusively to depletion of cortical ACh, these findings strongly support the direct involvement of p75NTR rich cholinergic axons in clearance of cortical Aβ. Finally, the dual neuro-modulator and homeostatic functions of cholinergic projections received experimental support from studies of AD brain autopsies, which highlighted considerable topographic overlap between the cortical areas undergoing extensive loss of cholinergic axons and those with Aβ load (Davies and Maloney, 1976; Geula and Mesulam, 1996). Noteworthy, diffuse cholinergic projections with a large fraction of terminal varicosities lacking post-synaptic specializations (Descarries et al., 1997), appear highly suited for effective sequestration and removal of Aβ from target fields.
It is now over a century since the German psychiatrist Alois Alzheimer presented the results of the first case study of a then obscure brain disorder at the local meeting of neurologists and psychiatrists in Tübingen. The disease, according to Alzheimer, manifests in a variety of symptoms affecting first the “memory and judgment, emotion and will” and with time “the power of observation becomes blunted, old memories and experiences no longer resonate… and nothing remains of the earlier personality” (Maurer and Maurer, 1998). Although this first report failed to capture the interest of the scientific community of those days and soon fell into oblivion, the case presented then heralded the rise of one of the most prevalent and devastating neurodegenerative disorders of the modern age, which relentlessly crumbles all that is humane in millions affected worldwide. In spite of the considerable advances and tough lessons since the beginning of the 20th century, the rising need in effective therapies against AD dwells as blatant testimony to the shortage of knowledge and understanding of arguably one of the greatest puzzles of the Universe residing behind our eyes—the human brain.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
This work was supported by German Center for Neurodegenerative Disease Research (DZNE), Munich, Germany and Deutsche Forschungegemeinschaft (SFB 596, A13), the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, 13N11130). Authors thank Dr. Valerie B. O'Leary for proofreading the manuscript.
Costantini, C., Della-Bianca, V., Formaggio, E., Chiamulera, C., Montresor, A., and Rossi, F. (2005). The expression of p75 neurotrophin receptor protects against the neurotoxicity of soluble oligomers of beta-amyloid. Exp. Cell Res. 311, 126–134. doi: 10.1016/j.yexcr.2005.09.004
Coulson, E. J., May, L. M., Sykes, A. M., and Hamlin, A. S. (2009). The role of the p75 neurotrophin receptor in cholinergic dysfunction in Alzheimer's disease. Neuroscientist 15, 317–323. doi: 10.1177/1073858408331376
Counts, S. E., and Mufson, E. J. (2005). The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J. Neuropathol. Exp. Neurol. 64, 263–272.
Davis, K. L., Mohs, R. C., Marin, D., Purohit, D. P., Perl, D. P., Lantz, M., et al. (1999). Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281, 1401–1406. doi: 10.1001/jama.281.15.1401
Fisher, A. (2012). Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease. J. Neurochem. 120(Suppl. 1), 22–33. doi: 10.1111/j.1471-4159.2011.07507.x
Francis, P. T., Palmer, A. M., Snape, M., and Wilcock, G. K. (1999). The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 66, 137–147. doi: 10.1136/jnnp.66.2.137
Hartig, W., Seeger, J., Naumann, T., Brauer, K., and Bruckner, G. (1998). Selective in vivo fluorescence labelling of cholinergic neurons containing p75(NTR) in the rat basal forebrain. Brain Res. 808, 155–165. doi: 10.1016/S0006-8993(98)00792-6
Knowles, J. K., Rajadas, J., Nguyen, T. V., Yang, T., LeMieux, M. C., Vander Griend, L., et al. (2009). The p75 neurotrophin receptor promotes amyloid-beta(1-42)-induced neuritic dystrophy in vitro and in vivo. J. Neurosci. 29, 10627–10637. doi: 10.1523/JNEUROSCI.0620-09.2009
Laursen, B., Mork, A., Plath, N., Kristiansen, U., and Bastlund, J. F. (2013). Cholinergic degeneration is associated with increased plaque deposition and cognitive impairment in APPswe/PS1dE9 mice. Behav. Brain Res. 240, 146–152. doi: 10.1016/j.bbr.2012.11.012
Mufson, E. J., Counts, S. E., Perez, S. E., and Ginsberg, S. D. (2008). Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev. Neurother. 8, 1703–1718. doi: 10.1586/1473722.214.171.1243
Nitsch, R. M., Slack, B. E., Farber, S. A., Borghesani, P. R., Schulz, J. G., Kim, C., et al. (1993). Receptor-coupled amyloid precursor protein processing. Ann. N.Y. Acad. Sci. 695, 122–127. doi: 10.1111/j.1749-6632.1993.tb23039.x
Ovsepian, S. V., Antyborzec, I., O'Leary, V. B., Zaborszky, L., Herms, J., and Oliver Dolly, J. (2013). Neurotrophin receptor p75 mediates the uptake of the amyloid beta (Abeta) peptide, guiding it to lysosomes for degradation in basal forebrain cholinergic neurons. Brain Struct. Funct. doi: 10.1007/s00429-013-0583-x. [Epub ahead of print].
Ovsepian, S. V., and Herms, J. (2013). Drain of the brain: low-affinity p75 neurotrophin receptor affords a molecular sink for clearance of cortical amyloid beta by the cholinergic modulator system. Neurobiol. Aging. 34, 2517–2524. doi: 10.1016/j.neurobiolaging.2013.05.005
Rajendran, L., Honsho, M., Zahn, T. R., Keller, P., Geiger, K. D., Verkade, P., et al. (2006). Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc. Natl. Acad. Sci. U.S.A. 103, 11172–11177. doi: 10.1073/pnas.0603838103
Terry, A. V. Jr., and Buccafusco, J. J. (2003). The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J. Pharmacol. Exp. Ther. 306, 821–827. doi: 10.1124/jpet.102.041616
Trajkovic, K., Hsu, C., Chiantia, S., Rajendran, L., Wenzel, D., Wieland, F., et al. (2008). Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 319, 1244–1247. doi: 10.1126/science.1153124
Wang, Y. J., Wang, X., Lu, J. J., Li, Q. X., Gao, C. Y., Liu, X. H., et al. (2011). p75NTR regulates Abeta deposition by increasing Abeta production but inhibiting Abeta aggregation with its extracellular domain. J. Neurosci. 31, 2292–2304. doi: 10.1523/JNEUROSCI.2733-10.2011
Yaar, M., Zhai, S., Pilch, P. F., Doyle, S. M., Eisenhauer, P. B., Fine, R. E., et al. (1997). Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. J. Clin. Invest. 100, 2333–2340. doi: 10.1172/JCI119772
Zarow, C., Lyness, S. A., Mortimer, J. A., and Chui, H. C. (2003). Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60, 337–341. doi: 10.1001/archneur.60.3.337
Keywords: neurodegenerative disorders, Alzheimer's disease, p75 neurotrophin receptor, basal forebrain cholinergic neurons, amyloid β
Citation: Ovsepian SV and Herms J (2013) Cholinergic neurons—keeping check on amyloid β in the cerebral cortex. Front. Cell. Neurosci. 7:252. doi: 10.3389/fncel.2013.00252
Received: 02 July 2013; Accepted: 22 November 2013;
Published online: 11 December 2013.
Edited by:Lawrence Rajendran, University Zurich, Switzerland
Reviewed by:Pietro Calissano, European Brain Research Institute, Italy
Lawrence Rajendran, University Zurich, Switzerland
Copyright © 2013 Ovsepian and Herms. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Saak V. Ovsepian, Center for Neuropathology and Prion Research, Ludwig Maximilian University, Feodor-Lynen-Str. 23, München, Germany e-mail: email@example.com